Literature DB >> 32312770

Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever.

Hanne Van Gorp1,2, Linyan Huang1,2,3, Pedro Saavedra1,2, Marnik Vuylsteke4, Tomoko Asaoka1,2, Giusi Prencipe5, Antonella Insalaco5, Benson Ogunjimi6,7,8,9,10,11, Jerold Jeyaratnam12, Ilaria Cataldo13, Peggy Jacques1,14, Karim Vermaelen2,15, Melissa Dullaers1,16, Rik Joos11,17, Vito Sabato11,18, Alessandro Stella19, Joost Frenkel12, Fabrizio De Benedetti5, Joke Dehoorne1,14, Filomeen Haerynck16,20, Giuseppe Calamita13, Piero Portincasa21, Mohamed Lamkanfi22,2.   

Abstract

BACKGROUND AND
OBJECTIVE: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AID) worldwide. The disease is caused by mutations in the MEFV gene encoding the inflammasome sensor Pyrin. Clinical diagnosis of FMF is complicated by overlap in symptoms with other diseases, and interpretation of genetic testing is confounded by the lack of a clear genotype-phenotype association for most of the 340 reported MEFV variants. In this study, the authors designed a functional assay and evaluated its potential in supporting FMF diagnosis.
METHODS: Peripheral blood mononuclear cells (PBMCs) were obtained from patients with Pyrin-associated autoinflammation with an FMF phenotype (n=43) or with autoinflammatory features not compatible with FMF (n=8), 10 asymptomatic carriers and 48 healthy donors. Sera were obtained from patients with distinct AIDs (n=10), and whole blood from a subset of patients and controls. The clinical, demographic, molecular genetic factors and other characteristics of the patient population were assessed for their impact on the diagnostic test read-out. Interleukin (IL)-1β and IL-18 levels were measured by Luminex assay.
RESULTS: The ex vivo colchicine assay may be performed on whole blood or PBMC. The functional assay robustly segregated patients with FMF from healthy controls and patients with related clinical disorders. The diagnostic test distinguished patients with classical FMF mutations (M694V, M694I, M680I, R761H) from patients with other MEFV mutations and variants (K695R, P369S, R202Q, E148Q) that are considered benign or of uncertain clinical significance.
CONCLUSION: The ex vivo colchicine assay may support diagnosis of FMF and functional subtyping of Pyrin-associated autoinflammation. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  familial mediterranean fever; fever syndromes; inflammation

Year:  2020        PMID: 32312770     DOI: 10.1136/annrheumdis-2019-216701

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

Review 1.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

2.  The unsolved mystery of MEFV variants variable expressivity in Familial Mediterranean Fever.

Authors:  Alessandro Stella; Piero Portincasa
Journal:  Intern Emerg Med       Date:  2022-07-09       Impact factor: 5.472

Review 3.  Induced Pluripotent Stem Cell-Derived Monocytes/Macrophages in Autoinflammatory Diseases.

Authors:  Takayuki Tanaka; Takeshi Shiba; Yoshitaka Honda; Kazushi Izawa; Takahiro Yasumi; Megumu K Saito; Ryuta Nishikomori
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 4.  [Genetic diagnostics of autoinflammatory diseases].

Authors:  Oskar Schnappauf
Journal:  Z Rheumatol       Date:  2020-09       Impact factor: 1.372

Review 5.  Familial Mediterranean Fever and COVID-19: Friends or Foes?

Authors:  Alessandro Stella; Mohamed Lamkanfi; Piero Portincasa
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

Review 6.  Multifactorial Rare Diseases: Can Uncertainty Analysis Bring Added Value to the Search for Risk Factors and Etiopathogenesis?

Authors:  Domenica Taruscio; Alberto Mantovani
Journal:  Medicina (Kaunas)       Date:  2021-01-28       Impact factor: 2.430

7.  Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever disease

Authors:  Taner Akyol; Tolga Düzenli; Alpaslan Tanoğlu
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 8.  Therapeutic modulation of inflammasome pathways.

Authors:  Dhruv Chauhan; Lieselotte Vande Walle; Mohamed Lamkanfi
Journal:  Immunol Rev       Date:  2020-08-07       Impact factor: 12.988

Review 9.  Gut Microbiota between Environment and Genetic Background in Familial Mediterranean Fever (FMF).

Authors:  Agostino Di Ciaula; Alessandro Stella; Leonilde Bonfrate; David Q H Wang; Piero Portincasa
Journal:  Genes (Basel)       Date:  2020-09-03       Impact factor: 4.096

10.  Phenotypic characterization of Familial Mediterranean Fever patients harboring variants of uncertain significance

Authors:  Alper Sarı; Erdal Bodakçi; Berkan Armağan; Hasan Satış; Nuh Ataş; Nazife Şule Yaşar Bilge; Reyhan Bilici Salman; Gözde Kübra Yardımcı; Hakan Babaoğlu; Levent Kılıç; Mehmet Akif Öztürk; Şeminur Haznedaroğlu; Berna Göker; Umut Kalyoncu; Timuçin Kaşifoğlu; Abdurrahman Tufan
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.